Clinical trial
A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV…
NCT00002204 · Chiron Corporation, Industry · Completed
Key facts
| NCT number | NCT00002204 |
|---|---|
| Title | A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults |
| Official title | A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults |
| Lead sponsor | Chiron Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | HIV p24/MF59 Vaccine |
| Enrollment | 40 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: